Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Nivolumab

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT03728361Phase 2Completed

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Nivolumab1
  • Temozolomide1

Active Sponsors

  • Bristol-Myers Squibb1
  • Dwight Owen1

Top Investigators

Related Conditions

  • Lung Cancer Stage Iv1
  • Metastatic Neuroendocrine Carcinoma1
  • Grade Iii Neuroendocrine Carcinoma1
  • Grade I Neuroendocrine Carcinoma1
  • Neuroendocrine Carcinoma1

Activity Timeline